Conclusion
muscle pain
In conclusion, letrozole treatment caused complete suppression of both E2 and E1 when measured by our highly sensitive LC–MS/MS assay. A high pretreatment E2 level was associated with more frequent joint and muscle pain during letrozole treatment. Our commercial chemiluminescent immunoassay for serum E2 had no value in assessing these low estrogen levels.